Given the therapeutic efficacy of [177Lu]-J591, this finding shows that J591 targets an epitope on the extracellular domain of PSMA solely available on PSMA exposed to prostate cancer cells and not on healthy cells. This evidence concerns the gene FOLH1 and Familial prostate cancer.